Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Safety and Efficacy of Prestige Coils for Embolization of Vascular Abnormalities: The Embo-Prestige Study

Julien Frandon
* ORCID logo ,
Romaric Loffroy
ORCID logo ,
Clement Marcelin
ORCID logo ,
Hélène Vernhet-Kovacsik
,
Joel Greffier
ORCID logo ,
Djamel Dabli
ORCID logo ,
Skander Sammoud
,
Pierre Marek
,
Olivier Chevallier
ORCID logo ,
Jean-Paul Beregi
,
Hervé Rousseau
Version 1 : Received: 28 August 2023 / Approved: 28 August 2023 / Online: 31 August 2023 (12:33:19 CEST)

A peer-reviewed article of this Preprint also exists.

Frandon, J.; Loffroy, R.; Marcelin, C.; Vernhet-Kovacsik, H.; Greffier, J.; Dabli, D.; Sammoud, S.; Marek, P.; Chevallier, O.; Beregi, J.-P.; Rousseau, H. Safety and Efficacy of Prestige Coils for Embolization of Vascular Abnormalities: The Embo-Prestige Study. J. Pers. Med. 2023, 13, 1464. Frandon, J.; Loffroy, R.; Marcelin, C.; Vernhet-Kovacsik, H.; Greffier, J.; Dabli, D.; Sammoud, S.; Marek, P.; Chevallier, O.; Beregi, J.-P.; Rousseau, H. Safety and Efficacy of Prestige Coils for Embolization of Vascular Abnormalities: The Embo-Prestige Study. J. Pers. Med. 2023, 13, 1464.

Abstract

: Background: A wide variety of coils are available for vascular embolization. This study aims to evaluate the safety and efficacy of a new Prestige coil. Method: Retrospective analysis of a multicentre registry data collected between February 2022 and November 2022. The choice of the embolization agent used was left at the investigator’s discretion to treat peripheral vascular anomalies. Patients for whom at least one Prestige coil was used were included in Series 1. All other patients were included in Series 2. Efficacy and safety were evaluated. Patients were followed up for one month. Results: 220 patients were included, 110 in each series. Patients were 149 men (67.7%) and 71 women (32.3%), of median age 62.5 years [IQR: 35.8-73], similar in the two series. The complete occlusion of the targeted vessel was reported in 96.4% (N=106/110) in Series 1 and in 99.7% (N=109/110) in Series 2. 4 patients experienced non-serious adverse events (1.8%, N=4/220): 1 back pain, 1 vomiting in Series 1, 1 off-target embolization and 1 puncture site hematoma in Series 2. 16 patients (7.2%, N=16/220) were lost to follow up. Improvement of the patient’s general state at one month was reported in 79.0% (N=83/105) in Series 1 and in 74.7% (N=74/99) in Series 2. 10 deaths occurred, 5 in Series 1 (4.8 %, N=5/105) and 5 in Series 2 (5.1%, N=5/99). They all concerned critically ill patients embolized for emergent arterial bleeding. Conclusion: the 1-month follow-up showed that the Prestige coils, alone or in combination, are efficient and safe.

Keywords

interventional radiology; embolization; peripheral vascular lesions; coils; safety

Subject

Medicine and Pharmacology, Cardiac and Cardiovascular Systems

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.